Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 199.20

+0.1%

Nov 21 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Andrew H who wrote (4279)	7/26/1997 9:10:00 AM
From: Henry Niman	of 32384

Here's more on Sankyo (Noscal is the Japanese brand name for Rezulin): Sales Start-up Slated For Sankyo Antidiabetic Source: Comline Comline Biotechnology Wire -- Sankyo Co. has resumed preparations for start-up by next March of sales of "Noscal," an antidiabetic for oral use since its safety has recently been confirmed by a study group attached to the Central Pharmaceutical Affairs Council. The leading Japanese drug maker obtained government production approval in September last year but decided last March to put off commercialization of the product itself, taking into account that in U.S. animal tests it proved responsible for increased frequency of vascular tumor in mice. Sankyo expects domestic sales of Noscal to amount to several ten billion yen ($1=JPY110) per annum. Regarding it an international strategic item, the company applied production approval stateside last September and is looking to do so in Europe next spring. It has granted Warner-Lambert (U.S.) and Glaxo Wellcome (U.K.) the marketing rights, valid for the States and Europe, respectively, for the promising diabetes remedy. Des: ZSC00/ZG000/ZHB10 Ref: Japan Chemical Week, 11/21/96, p. 06

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next